LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Accueil・Liste d'Actions・IQVIA Holdings Inc

IQVIA Holdings Inc

Ouvert

Secteur Soins de santé

210.38 0.57

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

204.7

Max

210.76

Chiffres clés
By Trading Economics
Revenu	-78M 285M
Ventes	90M 3.9B
P/E Moyenne du Secteur	28.89 104.138
BPA	2.84
Marge bénéficiaire	7.308
Employés	87,000
EBITDA	-12M 856M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+24.53 upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-4.9B 37B
Ouverture précédente	209.81
Clôture précédente	210.38

Sentiment de l'Actualité

By Acuity

50%

167 / 390 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

200.3 / 214.63 Support & Résistance

IQVIA Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 nov. 2024, 23:05 UTC

Actualités

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3 nov. 2024, 21:12 UTC

Résultats

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3 nov. 2024, 20:59 UTC

Résultats

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3 nov. 2024, 23:34 UTC

Actualités

Stocks Poised for Lower Open -- Barrons.com

3 nov. 2024, 23:16 UTC

Actualités

Résultats

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3 nov. 2024, 22:50 UTC

Acquisitions, Fusions, Rachats

Santos Says Working Interest in PNG LNG Now 39.9%

3 nov. 2024, 22:50 UTC

Acquisitions, Fusions, Rachats

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3 nov. 2024, 22:49 UTC

Acquisitions, Fusions, Rachats

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3 nov. 2024, 22:49 UTC

Acquisitions, Fusions, Rachats

Santos Receives Final $241 Million Payment From Kumul

3 nov. 2024, 22:48 UTC

Acquisitions, Fusions, Rachats

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3 nov. 2024, 20:37 UTC

Résultats

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3 nov. 2024, 20:36 UTC

Résultats

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3 nov. 2024, 20:35 UTC

Résultats

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3 nov. 2024, 20:35 UTC

Résultats

Westpac Raises Share Buyback Program by A$1 Billion

3 nov. 2024, 20:35 UTC

Résultats

Westpac Final Dividend A$0.76/Share

3 nov. 2024, 20:33 UTC

Résultats

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3 nov. 2024, 20:32 UTC

Résultats

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3 nov. 2024, 20:32 UTC

Résultats

Westpac FY Net Profit A$6.99 Billion, Down 3%

3 nov. 2024, 18:09 UTC

Actualités

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3 nov. 2024, 10:30 UTC

Actualités

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3 nov. 2024, 03:00 UTC

Actualités

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2 nov. 2024, 13:53 UTC

Actualités

Résultats

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov. 2024, 13:44 UTC

Résultats

Acquisitions, Fusions, Rachats

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 13:00 UTC

Actualités

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov. 2024, 12:58 UTC

Résultats

Acquisitions, Fusions, Rachats

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:48 UTC

Actualités

Résultats

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov. 2024, 12:32 UTC

Résultats

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Comparaison

Variation de prix

IQVIA Holdings Inc prévision

Objectif de Prix

By TipRanks

24.53% hausse

Prévisions sur 12 Mois

Moyen 260.46 USD 24.53%

Haut 279 USD

Bas 235 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

200.3 / 214.63Support & Résistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

167 / 390Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos IQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.